No full text
Article (Scientific journals)
Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.
Dahlof, C.; Hogenhuis, L.; Olesen, J. et al.
1998In European Journal of Neurology, 5 (5), p. 469-477
Peer Reviewed verified by ORBi
 

Files


Full Text
No document available.

Send to



Details



Abstract :
[en] Naratriptan is a novel, potent agonist at the 5HT1B/1D receptor. A total of 335 migraine patients were treated in this randomized, double-blind, placebo-controlled, dose-ranging, in-clinic study, to evaluate the efficacy, safety and tolerability of five doses of subcutaneous (sc) naratriptan (0.5, 1, 2.5, 5 or 10 mg) in comparison with sc sumatriptan (6 mg) and placebo in the acute treatment of a moderate/severe migraine attack. Headache relief [reduction of headache severity from moderate or severe (grade 2/3) to mild or none (grade 1/0)] at 1 and 2 h after each dose, was reported by a statistically significantly higher proportion of patients for all doses of sc naratriptan and sc sumatriptan (6 mg) than for placebo. The percentages of patients with headache relief at 2 h post-dose were: naratriptan (0.5 mg) 65%, (1 mg) 75%, (2.5 mg) 83%, (5 mg) 94% and (10 mg) 91%; sumatriptan (6 mg) 89%; placebo 41%, (P < 0.005). The earliest report of a statistically significant difference compared with placebo for the times assessed was with sc naratriptan (10 mg) at 10 min post-dose (P = 0.023). The percentages of patients reporting adverse events were dose-related; sc naratriptan (0.5 mg) 33%, (1 mg) 29%, (2.5 mg) 43%, (5 mg) 59% and (10 mg) 71%; sc sumatriptan 53%; placebo 22%. There were no clinically significant changes in electrocardiogram (ECG), vital signs or laboratory parameters. Systemic exposure increased proportionally to the dose, the absorption of sc naratriptan was rapid (tmax = 10 min) and the half-life was 5 h. In conclusion, sc naratriptan was an effective and well-tolerated acute treatment for migraine. Copyright 1998 Lippincott Williams & Wilkins
Disciplines :
Neurosciences & behavior
Neurology
Author, co-author :
Dahlof, C.
Hogenhuis, L.
Olesen, J.
Petit, H.
Ribbat, J.
Schoenen, Jean  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Boswell, D.
Fuseau, E.
Hassani, H.
Winter, P.
Language :
English
Title :
Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.
Publication date :
1998
Journal title :
European Journal of Neurology
ISSN :
1351-5101
eISSN :
1468-1331
Publisher :
Blackwell Science, Oxford, United Kingdom
Volume :
5
Issue :
5
Pages :
469-477
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 29 September 2009

Statistics


Number of views
86 (1 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
45
Scopus citations®
without self-citations
39
OpenCitations
 
43

Bibliography


Similar publications



Contact ORBi